Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvianolic acid for injection in ischemic stroke recovery
ChiCTR2000033556Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xingtai Medical College
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of danshen polyphenolic acid in ischemic stroke, sponsored by The Second Affiliated Hospital of Xingtai Medical College. Primary endpoint: Proportion of patients with mRS 0-1 at 90 days after treatment. Started May 2020; status: recruiting.
02
Drugs
danshen polyphenolic acid
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2000033556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033556.